Search company, investor...
Biocon company logo

Biocon

biocon.com

Founded Year

1978

Stage

IPO | IPO

Date of IPO

2/23/2004

Market Cap

342.41B

Revenue

$0000 

About Biocon

Biocon is a biotechnology enterprise. It focuses on biopharmaceuticals, custom research, clinical research and enzymes. The company leverages a combination of fermentation technologies and research skills in drug synthesis to propel its growth.

Headquarters Location

20th KM Hosur Road Electronic City

Bengaluru, 560 100,

India

+91 80 2808 2808

Missing: Biocon's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biocon's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Biocon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biocon is included in 1 Expert Collection, including Digital Health.

D

Digital Health

459 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

Biocon Patents

Biocon has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/19/2018

10/18/2022

Insulin therapies, Acoustics, Chemical processes, Peptide hormones, Diabetes

Grant

Application Date

9/19/2018

Grant Date

10/18/2022

Title

Related Topics

Insulin therapies, Acoustics, Chemical processes, Peptide hormones, Diabetes

Status

Grant

Latest Biocon News

Hot Stocks | Here#39;s why should bet on Sterlite Technologies, Biocon for short term

Nov 21, 2022

Sterlite Technologies has managed to traverse the key moving average of ‘200-day SMA’ (simple moving average) with some conviction after a long time, which construes a strong technical development. Sameet Chavan Trade × With the weekly closure, the Nifty snapped its four weeks of winning streak and settled a tad above the 18,300 level on November 18. It had been a lacklustre week for the market participants as the follow-up buying was clearly missing to uplift the market, and this resulted in a lull movement in the benchmark index. Global concerns over rising inflation have led to mixed action, mirroring which the market remained tentative at the higher levels. On the technical front, the structure remains upbeat. As far as levels are concerned, the bullish gap of 18,100-18,250 is likely to provide a cushion to any intra-week blip, and it is highly anticipated that the dip would augur well for the bulls. On the flip side, 18,450-18,500 is a significant hurdle for the bulls, and any decisive breach above the same could only trigger a fresh round of rally in the market. Meanwhile, the market awaits some trigger points to have an upsurge, and in the meantime, the index is expected to remain in the mentioned range. We remain sanguine with the uptrend and would advocate the traders to utilize the dips to add long position in the index. Also, despite the lethargic moves in the index throughout last week, some of the individual pockets kept buzzing. Related stories Hence, we expect some interesting moves to unfold in a larger pool of stocks, which is likely to provide better opportunities for momentum traders. We advise traders to stay with a similar buy on decline strategy till the time important supports are held comfortably. Here are two buy calls for short term: Sterlite Technologies : Buy | LTP: Rs 177.70 | Stop-Loss: Rs 168.40 | Target: Rs 195 | Return: 10 percent It has been hovering in a symmetrical triangle pattern on the daily chart and has seen some traction in terms of volume from the past couple of trading sessions. In the last session, the stock witnessed a volume-based break out of the pattern and is looking sturdy to continue its upward march in the near period. Also, the stock has managed to traverse the key moving average of ‘200-day SMA’ (simple moving average) with some conviction after a long time, which construes a strong technical development. Even the major technical indicators are in line with the uptrend, adding a bullish quotient to the counter. Thus, we recommend buying for a near term target of Rs 195. Traders can participate by following strict stop-loss at Rs 168.40. Biocon : Buy | LTP: Rs 287.35 | Stop-Loss: Rs 280 | Target: Rs 299 | Return: 4 percent This stock has been one of the worst performing stocks in last two years. The stock prices have been on a gradual decline mode all this while and have corrected more than 40 percent from its record highs. In last 3-4 weeks, the price correction seems to have arrested and we are seeing some early signs of revival in this stock. On a daily time frame chart, the stock has managed to close above Rs 287 which is a sign of strength. If we combine this with weekly chart, we can observe the ‘RSI-Smoothened’ oscillator confirming a positive crossover from oversold territory. Traders are advised to buy for a near term target of Rs 299. The strict stop-loss needs to be placed at Rs 280. Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. Sameet Chavan is the Chief Analyst-Technical and Derivatives at Angel One Ltd.

Biocon Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biocon Rank

Biocon Frequently Asked Questions (FAQ)

  • When was Biocon founded?

    Biocon was founded in 1978.

  • Where is Biocon's headquarters?

    Biocon's headquarters is located at 20th KM Hosur Road, Bengaluru.

  • What is Biocon's latest funding round?

    Biocon's latest funding round is IPO.

  • Who are Biocon's competitors?

    Competitors of Biocon include AmideBio, Biolog, c-LEcta, Kedrion, Clinipace, Molmed, Bloomage BioTech, Integrated DNA Technologies, Irvine Pharmaceutical Services, ReInnervate and 16 more.

Compare Biocon to Competitors

C
CELBIO SpA

SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

A
Akron Biotechnology

Akron Biotechnology provides its customers with quality raw materials and components for research and development. As a scientific product supplier, the company specializes in manufacturing and supplying chemicals, biochemicals, cell culture, and cell biology products aimed at the biopharmaceutical and biotechnology markets.

VitrOmics Logo
VitrOmics

VitrOmics (formerly PamGene) develops valuable knowledge and tools in the field of Predictive Genomics. The necessary research are carried out by using in vitro exposure systems based on human cells and applying the latest genomics technologies.

A
Angel Biotechnology

Angel Biotechnology Holdings PLC (AIM: ABH) is a world class, contract biomanufacturing company offering process development services and pre-GMP and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. nnAngel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo and Serologicals Inc. nnAngel operates out of Pentlands Science Park, near Edinburgh.

Biolog Logo
Biolog

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

A
Athena Environmental Sciences

AthenaES specializes in the development and commercialization of advanced biotechnology-based products. Throughout its eleven year history, the company has maintained a broad perspective for applying its core competency, the use of proteins and enzymes for commercial applications, to develop products. As such, the company currently markets its products and services through two business units and maintains an exploratory R&D group. The Athena Enzyme Systems Group aims to provide specialty reagents and proteins for the production and recovery of recombinant proteins along with providing contract R&D services. Products include: Expression Media, Serum-free Media, Protein Refolding kits, and the PDQ Protease Assay. This business unit also aims to provide specialized contract research, development and manufacturing services for the production of recombinant proteins. The Athena Environmental Services Group designs, develops and manufactures environmentally responsible products. Products developed include: The Bilge Pill, a biodegradable cleaning product for the removal of oil in boat bilges, and a plant nutrient supplement used in hydroponics, hobby gardens and horticulture that replaces conventional fertilizers, and the Sting Thing, an enzyme-based invertebrate sting treatment product. More recently, this group developed and has introduced a water-soluble, reversible glue, MagiGlue. The Athena Exploratory Science Group has the mission to pursue research with the potential for commercial, environmental and social impact. These projects are far reaching in their scope and represent high risk, high-value projects.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.